Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 3, 2010, Pages 365-367

  Song, Ivy ^a   Min, Sherene S ^a   Borland, Julie ^a   Lou, Yu ^a   Chen, Shuguang ^a   Ishibashi, Toru ^b   Wajima, Toshihiro ^b   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

antiretroviral; HIV 1; integrase inhibitor; S GSK1349572

Indexed keywords

INTEGRASE INHIBITOR; S GSK 1349572; TENOFOVIR; UNCLASSIFIED DRUG; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ABNORMAL LABORATORY RESULT; ADULT; ARTHRALGIA; ARTICLE; DIARRHEA; DRUG INDUCED HEADACHE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; VITAL SIGN; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG INTERACTION; MIDDLE AGED; PLASMA;

ADENINE; ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HIV INTEGRASE INHIBITORS; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PLASMA; ORGANOPHOSPHONATES;

EID: 78049297410     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e67909     Document Type: Article

References (9)

1. Sato A, Kobayashi M, Yoshinaga T, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor. Poster presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
2. Min S, Song I, Borland J, et al. Pharmacokinetics and safety in healthy subjects of S/GSK1349572, a next generation HIV integrase inhibitor in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-258.
3. Lalezari J, Sloan L, DeJesus E, et al. Potent antiviral activity of S/ GSK1349572, a next generation integrase inhibitor (INI), in INI-näve HIV-1-infected patients. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
4. Underwood M, Johns B, Sato A, et al. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. Poster presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
5. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol. 2005;45:1360-1367.
6. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-2096.
7. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304.
8. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemo-ther. 2008;52:3253-3258.
9. Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/ tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr. 2007;45:274-279.